Review article · 2023 · Open access

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Jin Li, Xinxin Chen, Aiping Lü, Chao Liang

The Innovation, 4(3), 100413 · Published 15 March 2023 · DOI 10.1016/j.xinn.2023.100413

Open PDFView at the publisherCite this paper

In brief

“Targeted protein degradation in cancers: Orthodox PROTACs and beyond” is a 2023 review article by Jin Li and 3 co-authors, published in The Innovation. OpenAlex counts 95 citations as of 21 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at The Innovation.

Citations
95
Most cited in
2026 (34)
Field-weighted impact
2.12
References
230
Authors
4

Abstract

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of traditional small-molecule inhibitors. Proteolysis-targeting chimera (PROTAC) technology can be used to target proteins by hijacking the ubiquitin-proteasome system. Conceptually, PROTAC aims to target the "undruggable" majority of proteins in the human proteome. Through constant exploration and optimization of PROTACs and the exploitation of other TPD strategies over two decades, TPD has expanded from theoretical studies to clinical strategies, with practical applications in oncological, immunological, and other diseases. In this review, we introduce the mechanisms, features, and molecular targets of orthodox PROTACs and summarize the PROTAC drugs under study as cancer therapeutics in clinical trials. We also discuss PROTAC derivatives and other TPD strategies, such as lysosome-targeting chimeras, autophagy-targeting chimeras, and molecular glue strategies. Collectively, the studies summarized herein support the full potential of TPD in the biomedical industry.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Li, J., Chen, X., Lü, A., & Liang, C. (2023). Targeted protein degradation in cancers: Orthodox PROTACs and beyond. The Innovation, 4(3), 100413. https://doi.org/10.1016/j.xinn.2023.100413

MLA 9

Li, Jin, et al. “Targeted protein degradation in cancers: Orthodox PROTACs and beyond.” The Innovation, vol. 4, no. 3, 2023, p. 100413. https://doi.org/10.1016/j.xinn.2023.100413.

Chicago

Li, Jin, Xinxin Chen, Aiping Lü, and Chao Liang. 2023. “Targeted protein degradation in cancers: Orthodox PROTACs and beyond.” The Innovation 4 (3): 100413. https://doi.org/10.1016/j.xinn.2023.100413.

Harvard

Li, J. et al. (2023) ‘Targeted protein degradation in cancers: Orthodox PROTACs and beyond’, The Innovation, 4(3), p. 100413. doi:10.1016/j.xinn.2023.100413.

IEEE

J. Li, X. Chen, A. Lü, and C. Liang, “Targeted protein degradation in cancers: Orthodox PROTACs and beyond,” The Innovation, vol. 4, no. 3, p. 100413, 2023, doi: 10.1016/j.xinn.2023.100413.

BibTeX

@article{li2023targeted,
  title     = {{Targeted protein degradation in cancers: Orthodox PROTACs and beyond}},
  author    = {Li, Jin and Chen, Xinxin and Lü, Aiping and Liang, Chao},
  journal   = {The Innovation},
  year      = {2023},
  volume    = {4},
  number    = {3},
  pages     = {100413},
  doi       = {10.1016/j.xinn.2023.100413},
  url       = {https://doi.org/10.1016/j.xinn.2023.100413}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202377
20242424
20253030
20263434

Its field-weighted citation impact is 2.12: it has been cited 2.12 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • targeted protein degradation
  • PROTACs
  • ubiquitin-proteasome system
  • cancer therapeutics
  • undruggable proteins
  • lysosome-targeting chimeras
  • molecular glues
  • clinical trials

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Li, J., Chen, X., Lü, A., & Liang, C. (2023). Targeted protein degradation in cancers: Orthodox PROTACs and beyond. The Innovation, 4(3), 100413. https://doi.org/10.1016/j.xinn.2023.100413

How many times has this paper been cited?

95 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Innovation: sign in and open the PDF from this page.

Who wrote this paper?

Jin Li, Xinxin Chen, Aiping Lü, Chao Liang.

What is the DOI of this paper?

10.1016/j.xinn.2023.100413, permanently at https://doi.org/10.1016/j.xinn.2023.100413. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.